The generic name for the drug daridorexant is daridorexant [1]. Daridorexant is marketed under the brand name Quviviq [2].
What is Daridorexant used for?
Daridorexant is used to treat insomnia characterized by difficulties with sleep onset and/or sleep maintenance [2]. It functions by blocking orexin receptors, which are responsible for promoting wakefulness [3].
When does Daridorexant's patent expire?
The patent landscape for daridorexant is complex, with multiple patents covering the drug and its uses. According to DrugPatentWatch.com, patent expiry dates can vary based on specific patents and potential extensions. For detailed information on patent expiry dates and exclusivities, DrugPatentWatch.com provides a comprehensive resource [4].
How does Daridorexant compare to other insomnia medications?
Daridorexant is a dual orexin receptor antagonist, a different mechanism of action compared to older insomnia medications like benzodiazepines and non-benzodiazepine hypnotics (e.g., zolpidem, zopiclone), which act on GABA receptors [3][5]. Orexin receptor antagonists are designed to reduce the stimulation of wakefulness pathways, aiming to improve sleep without the same sedation profile associated with some other classes [3].
What are the potential side effects of Daridorexant?
Common side effects reported for daridorexant include somnolence (sleepiness) and headache [2]. Patients are advised to avoid driving or operating heavy machinery after taking daridorexant due to the risk of impaired alertness [2].
Who developed Daridorexant?
Daridorexant was developed by Idorsia Pharmaceuticals [2].
What is the regulatory status of Daridorexant?
Daridorexant has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of insomnia [2][6].
What clinical data supports Daridorexant's efficacy?
Clinical trials have demonstrated that daridorexant improves sleep onset and sleep maintenance in adults with insomnia [2][7]. Studies have measured efficacy using objective measures like polysomnography and subjective patient reports [7].
Are there any concerns about long-term use of Daridorexant?
Long-term safety and efficacy data continue to be evaluated as part of ongoing clinical practice and post-marketing surveillance. Patients should discuss any concerns about long-term treatment with their healthcare provider [2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215855s000lbl.pdf
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136462/
[4] https://www.drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024217/
[6] https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq
[7] https://www.nejm.org/doi/full/10.1056/nejmoa2114257